About: Cell Host Response to Infection with Novel Human Coronavirus EMC Predicts Potential Antivirals and Important Differences with SARS Coronavirus

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Cell Host Response to Infection with Novel Human Coronavirus EMC Predicts Potential Antivirals and Important Differences with SARS Coronavirus Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Cell Host Response to Infection with Novel Human Coronavirus EMC Predicts Potential Antivirals and Important Differences with SARS Coronavirus
Creator	Baric, Ralph Gralinski, Lisa Agnihothram, Sudhakar Yount, Boyd Josset, Laurence Carter, Victoria Menachery, Vineet Sova, Pavel Bl, Yount Graham, Rachel Katze, Michael Vd, Menachery Le, Gralinski Rl, Graham Vs, Carter
Source	Medline; PMC
abstract	A novel human coronavirus (HCoV-EMC) was recently identified in the Middle East as the causative agent of a severe acute respiratory syndrome (SARS) resembling the illness caused by SARS coronavirus (SARS-CoV). Although derived from the CoV family, the two viruses are genetically distinct and do not use the same receptor. Here, we investigated whether HCoV-EMC and SARS-CoV induce similar or distinct host responses after infection of a human lung epithelial cell line. HCoV-EMC was able to replicate as efficiently as SARS-CoV in Calu-3 cells and similarly induced minimal transcriptomic changes before 12 h postinfection. Later in infection, HCoV-EMC induced a massive dysregulation of the host transcriptome, to a much greater extent than SARS-CoV. Both viruses induced a similar activation of pattern recognition receptors and the interleukin 17 (IL-17) pathway, but HCoV-EMC specifically down-regulated the expression of several genes within the antigen presentation pathway, including both type I and II major histocompatibility complex (MHC) genes. This could have an important impact on the ability of the host to mount an adaptive host response. A unique set of 207 genes was dysregulated early and permanently throughout infection with HCoV-EMC, and was used in a computational screen to predict potential antiviral compounds, including kinase inhibitors and glucocorticoids. Overall, HCoV-EMC and SARS-CoV elicit distinct host gene expression responses, which might impact in vivo pathogenesis and could orient therapeutic strategies against that emergent virus.
has issue date	2013-04-30(xsd:dateTime)
bibo:doi	10.1128/mbio.00165-13
bibo:pmid	23631916
has license	cc-by-nc-sa
sha1sum (hex)	4edda548e89522b4df20e723e29c63f309857b10
schema:url	https://doi.org/10.1128/mbio.00165-13
resource representing a document's title	Cell Host Response to Infection with Novel Human Coronavirus EMC Predicts Potential Antivirals and Important Differences with SARS Coronavirus
has PubMed Central identifier	PMC3663187
has PubMed identifier	23631916
schema:publication	mBio
resource representing a document's body	covid:4edda548e89522b4df20e723e29c63f309857b10#body_text
is schema:about of	named entity 'induce' named entity 'SARS coronavirus' covid:arg/4edda548e89522b4df20e723e29c63f309857b10 named entity 'human' named entity 'genetically' named entity 'induced' named entity 'coronavirus' named entity 'SARS-CoV' named entity 'Potential' named entity 'Important' named entity 'causative agent' named entity 'HCoV-EMC' named entity 'SARS' named entity 'HCoV-EMC' named entity 'SARS-CoV' named entity 'Calu-3' named entity 'Human Coronavirus' named entity 'Antivirals' named entity 'Infection' named entity 'host response' named entity '2B4' named entity 'inflammatory bowel disease' named entity 'down-regulated' named entity 'host response' named entity 'HCoV-EMC' named entity 'SARS-CoV' named entity 'HCoV-EMC' named entity 'HCoV-EMC' named entity 'HCoV-EMC' named entity 'kinase inhibitors' named entity 'linear model' named entity 'emerging viruses' named entity 'transcriptomic' named entity 'SARS-CoV' named entity 'antiviral' named entity 'hpi' named entity 'down-regulated' named entity 'host response' named entity 'HCoV-EMC' named entity 'viral replication' named entity 'infection' named entity 'cAMP' named entity 'SB203580' named entity 'SARS-CoV' named entity 'MHC class II' named entity 'enrichment analyses' named entity 'viral infection' named entity 'SARS-CoV' named entity 'transcriptional' named entity 'Calu-3' named entity 'ACE2' named entity 'cell lines' named entity 'inflammatory disorder' named entity 'infection' named entity 'professional antigen-presenting cells' named entity 'Calu-3' named entity 'immune-mediated' named entity 'down-regulated' named entity 'host response' named entity 'HCoV-EMC' named entity 'HCoV-EMC' named entity 'MHC' named entity 'differentially expressed' named entity 'SB203580' named entity 'cellular processes' named entity 'SARS-CoV' named entity 'infection'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software